Lung Cancer: A Complete Guide for International Patients in Shanghai

Introduction

Lung cancer is the most commonly diagnosed cancer and the leading cause of cancer death worldwide, accounting for approximately 2.2 million new cases and 1.8 million deaths annually. In China, lung cancer is the number one cancer killer — China accounts for approximately 37% of all lung cancer cases globally, driven by high smoking rates, air pollution, occupational exposures, and a high prevalence of EGFR mutations in the Chinese population.

The landscape of lung cancer treatment has been transformed over the past decade. Molecular testing, targeted therapies, and immunotherapy have converted what was once a uniformly fatal diagnosis into a condition that many patients — particularly those with actionable mutations — can manage as a chronic disease for years. Early detection through low-dose CT screening is saving lives.

For international patients and expatriates in Shanghai, understanding lung cancer — from risk factors and screening to diagnosis and the latest treatments — is essential. This guide provides a comprehensive overview tailored to the international community in Shanghai.

Types of Lung Cancer

Lung cancer is broadly divided into two major categories based on cell type, which determines treatment approach:

Non-Small Cell Lung Cancer (NSCLC) — approximately 85% of cases

• Adenocarcinoma: The most common subtype, accounting for approximately 40% of all lung cancers. Arises in the peripheral lung tissue. More common in non-smokers and women. The subtype most likely to harbor actionable molecular alterations (EGFR, ALK, ROS1, KRAS, MET, RET, NTRK, BRAF). Particularly prevalent in Chinese patients — EGFR mutations occur in approximately 50% of Chinese adenocarcinoma patients, compared to 10–15% in Western populations.
• Squamous cell carcinoma: Arises in the central airways. Strongly associated with smoking. Less commonly harbors actionable mutations but may express PD-L1 and respond to immunotherapy.
• Large cell carcinoma: A diagnosis of exclusion; aggressive behavior.

Small Cell Lung Cancer (SCLC) — approximately 15% of cases

Strongly associated with smoking. Highly aggressive with rapid growth and early metastasis. Initially very sensitive to chemotherapy and radiation, but almost always relapses. Treated differently from NSCLC.

Other Rare Types

Carcinoid tumors, adenosquamous carcinoma, sarcomatoid carcinoma, and pulmonary lymphomas are less common.

Risk Factors

Smoking

Tobacco smoking is the single most important risk factor for lung cancer, responsible for approximately 85% of cases globally. The risk is proportional to the number of cigarettes smoked per day and the duration of smoking. Former smokers retain elevated risk for decades after quitting, though risk gradually declines.

Air Pollution — Particularly Relevant in Shanghai

Outdoor air pollution — particularly fine particulate matter (PM2.5) — is classified as a Group 1 carcinogen by the International Agency for Research on Cancer (IARC). China’s high levels of air pollution contribute significantly to the country’s lung cancer burden. Indoor air pollution from cooking fumes (particularly from high-temperature wok cooking with unventilated kitchens) is also a significant risk factor for lung cancer in Chinese women — many of whom are non-smokers.

Other Risk Factors

• Radon gas: A naturally occurring radioactive gas that accumulates in poorly ventilated buildings. The second leading cause of lung cancer after smoking.
• Occupational exposures: Asbestos, arsenic, chromium, nickel, beryllium, diesel exhaust
• Family history of lung cancer
• Prior lung disease: COPD, pulmonary fibrosis, and prior tuberculosis increase lung cancer risk
• Prior radiation therapy to the chest

Symptoms

Lung cancer is often asymptomatic in its early stages — which is why screening is so important. When symptoms do occur, they may include:

• Persistent cough that is new or has changed in character
• Coughing up blood (haemoptysis) — even small amounts warrant urgent evaluation
• Shortness of breath or worsening exercise tolerance
• Chest pain or discomfort
• Hoarseness (from recurrent laryngeal nerve involvement)
• Recurrent chest infections or pneumonia
• Unexplained weight loss and fatigue
• Loss of appetite

Symptoms of advanced or metastatic lung cancer may include:

• Bone pain (bone metastases)
• Headache, seizures, or neurological symptoms (brain metastases)
• Swelling of the face, neck, or arms (superior vena cava syndrome)
• Shoulder and arm pain (Pancoast tumor)

Any persistent respiratory symptom lasting more than 3 weeks — particularly in a current or former smoker — warrants medical evaluation.

Screening: Low-Dose CT (LDCT)

Low-dose CT (LDCT) screening of the chest is the only proven method for early lung cancer detection and has been shown to reduce lung cancer mortality by 20–24% in high-risk individuals.

Who Should Be Screened?

Current international guidelines (USPSTF, NCCN) recommend annual LDCT screening for:

• Adults aged 50–80 years
• With a smoking history of ≥20 pack-years (1 pack per day for 20 years, or equivalent)
• Who currently smoke or quit within the past 15 years

Chinese guidelines also recommend LDCT screening for non-smokers with other risk factors (air pollution exposure, family history, occupational exposures, prior lung disease). Given the high prevalence of lung cancer in non-smoking Chinese women, broader screening criteria are increasingly advocated.

LDCT screening is available at major Shanghai hospitals and international clinics. CMCS can coordinate lung cancer screening as part of a comprehensive health check-up.

Diagnosis

When lung cancer is suspected — based on symptoms, an abnormal chest X-ray, or a suspicious CT finding — the diagnostic workup includes:

• CT scan of the chest (with contrast): Characterizes the lung lesion and assesses mediastinal lymph nodes and pleural involvement.
• PET-CT scan: Assesses metabolic activity of the lung lesion and detects distant metastases. Essential for staging NSCLC. Available at major Shanghai hospitals.
• Brain MRI: To detect brain metastases, particularly in adenocarcinoma.
• Tissue biopsy: Definitive diagnosis requires histological confirmation. Biopsy approaches include:
  • CT-guided percutaneous needle biopsy: For peripheral lung lesions. Performed under CT guidance by an interventional radiologist.
  • Bronchoscopy with biopsy: For central airway lesions. Endobronchial ultrasound (EBUS) allows sampling of mediastinal lymph nodes.
  • Video-assisted thoracoscopic surgery (VATS): Minimally invasive surgical biopsy for lesions not accessible by other means, or for definitive resection.
  • Liquid biopsy (circulating tumor DNA): Blood-based testing for tumor DNA. Increasingly used for molecular profiling when tissue is insufficient, and for monitoring treatment response and resistance.
• Comprehensive molecular profiling: Essential for all NSCLC patients, particularly adenocarcinoma. Testing should include EGFR, ALK, ROS1, KRAS G12C, MET exon 14, RET, NTRK, BRAF V600E, HER2, and PD-L1 expression. Next-generation sequencing (NGS) panels covering all relevant alterations simultaneously are the standard of care at leading Shanghai centers.
• Staging: NSCLC is staged I–IV using the TNM system. Stage determines treatment intent (curative vs. palliative) and approach.

Treatment

Lung cancer treatment is highly individualized based on histological type, stage, molecular profile, PD-L1 expression, and patient performance status. A multidisciplinary team (MDT) approach is essential.

Stage I–II NSCLC: Curative Intent

• Surgery: The primary curative treatment for early-stage NSCLC. Lobectomy (removal of a lobe of the lung) is the standard procedure. Minimally invasive approaches (VATS or robotic-assisted thoracic surgery, RATS) are preferred at leading centers, offering faster recovery and equivalent oncological outcomes. Sublobar resection (segmentectomy or wedge resection) is appropriate for small tumors (≤2 cm) or patients with limited lung reserve. Available at major Shanghai thoracic surgery centers.
• Stereotactic body radiation therapy (SBRT / SABR): High-dose, precisely targeted radiation delivered in 3–5 sessions. An effective alternative to surgery for patients who are medically inoperable or decline surgery. Available at leading Shanghai radiation oncology centers.
• Adjuvant therapy after surgery:
  • Adjuvant chemotherapy (cisplatin-based) for Stage II–III disease
  • Adjuvant osimertinib: For EGFR-mutated Stage IB–IIIA NSCLC after complete resection. Dramatically reduces recurrence risk. Approved and available in China.
  • Adjuvant atezolizumab: For PD-L1 positive Stage II–IIIA NSCLC after resection and chemotherapy. Availability in China is expanding.

Stage III NSCLC: Locally Advanced

• Concurrent chemoradiation: The standard of care for unresectable Stage III NSCLC. Platinum-based chemotherapy is given concurrently with thoracic radiation therapy.
• Consolidation durvalumab (anti-PD-L1): Immunotherapy given after chemoradiation for patients without disease progression. Significantly improves survival. Approved and available in China.
• Surgery: Selected Stage IIIA patients may be candidates for surgical resection after neoadjuvant therapy, discussed at MDT.

Stage IV NSCLC: Metastatic — Targeted Therapy

Molecular profiling is essential before starting treatment. Targeted therapies produce dramatically superior outcomes compared to chemotherapy in patients with actionable mutations:

• EGFR mutations (exon 19 deletion, exon 21 L858R, and others): Present in approximately 50% of Chinese adenocarcinoma patients. First-line treatment: osimertinib (third-generation EGFR TKI) — the global standard of care. Approved and available in China. Alternatives: gefitinib, erlotinib, afatinib, dacomitinib (all available in China).
• ALK rearrangements: Present in approximately 5% of NSCLC. First-line treatment: alectinib or lorlatinib — highly effective with prolonged progression-free survival. Available in China.
• ROS1 rearrangements: Crizotinib, entrectinib, or lorlatinib. Available in China.
• KRAS G12C mutation: Sotorasib or adagrasib. Availability in China is expanding.
• MET exon 14 skipping: Tepotinib or capmatinib. Availability in China is expanding.
• RET rearrangements: Selpercatinib or pralsetinib. Available in China.
• NTRK fusions: Larotrectinib or entrectinib. Available in China.
• BRAF V600E: Dabrafenib + trametinib. Available in China.
• HER2 mutations: Trastuzumab deruxtecan (T-DXd). Availability in China is expanding.

Stage IV NSCLC: Metastatic — Immunotherapy

For patients without actionable mutations, immunotherapy has transformed outcomes:

• High PD-L1 expression (≥50%): Pembrolizumab monotherapy is first-line standard of care. Approved and available in China.
• PD-L1 any expression: Pembrolizumab + platinum-based chemotherapy (with or without bevacizumab for non-squamous). Approved and available in China.
• Squamous NSCLC: Pembrolizumab + carboplatin + paclitaxel/nab-paclitaxel. Available in China.
• Chinese domestic PD-1/PD-L1 inhibitors: Sintilimab, camrelizumab, tislelizumab, and others are approved in China and widely used, often at lower cost than imported agents.

Small Cell Lung Cancer (SCLC)

• Limited stage SCLC: Concurrent chemoradiation (cisplatin/etoposide + thoracic RT) followed by prophylactic cranial irradiation (PCI). Curative intent in selected patients.
• Extensive stage SCLC: Platinum-etoposide chemotherapy + atezolizumab or durvalumab (immunotherapy). Improves survival but disease almost always progresses.
• Relapsed SCLC: Topotecan or lurbinectedin. Prognosis is poor.

Chemotherapy

Platinum-based chemotherapy (cisplatin or carboplatin combined with pemetrexed, paclitaxel, gemcitabine, or docetaxel) remains the backbone of treatment for patients without actionable mutations and as second-line therapy. All agents are available in China.

Antiangiogenic Therapy

Bevacizumab (anti-VEGF) and ramucirumab are used in combination with chemotherapy or immunotherapy for non-squamous NSCLC. Available in China.

Lung Cancer in Non-Smokers

A significant and growing proportion of lung cancer — particularly in China — occurs in never-smokers. This is especially true for women with adenocarcinoma. Non-smoker lung cancer is more likely to harbor EGFR, ALK, or ROS1 alterations and responds well to targeted therapy. Air pollution, cooking fume exposure, and genetic factors are important contributors. Never-smokers with lung cancer should receive comprehensive molecular profiling to identify actionable targets.

Survivorship & Follow-Up

After curative treatment, regular surveillance is essential:

• CT chest every 6 months for 2 years, then annually
• Brain MRI annually for high-risk histologies
• Monitoring for treatment side effects: immune-related adverse events (from immunotherapy), peripheral neuropathy (from chemotherapy), interstitial lung disease (from EGFR TKIs and immunotherapy)
• Smoking cessation support — quitting after diagnosis improves outcomes
• Psychological support: anxiety and depression are common in lung cancer survivors

Lung Cancer Care in Shanghai

• Molecular testing: Comprehensive NGS-based molecular profiling is available at major Shanghai hospitals and commercial laboratories (e.g., Burning Rock, Genetron). This is essential for all NSCLC patients.
• Targeted therapies: Osimertinib, alectinib, lorlatinib, and most other targeted agents are approved and available in China. Chinese domestic TKIs (gefitinib, icotinib) are widely used and cost-effective.
• Immunotherapy: Both imported (pembrolizumab, atezolizumab, durvalumab) and domestic PD-1 inhibitors are available in China.
• Surgical expertise: VATS and robotic thoracic surgery are performed at Zhongshan Hospital, Shanghai Chest Hospital, and Ruijin Hospital by high-volume thoracic surgeons.
• MDT approach: Leading Shanghai hospitals conduct regular lung cancer MDT meetings involving thoracic surgeons, medical oncologists, radiation oncologists, radiologists, and pathologists.
• Liquid biopsy: Circulating tumor DNA testing is widely available in China through commercial laboratories and hospital-based platforms.

How China Medical Concierge Shanghai (CMCS) Can Help

A lung cancer diagnosis is one of the most challenging situations an international patient can face. Navigating treatment in a foreign healthcare system adds significant complexity. CMCS provides comprehensive support at every stage:

• Lung cancer screening coordination: Arranging LDCT screening for eligible high-risk individuals
• Specialist matching: Connecting you with leading thoracic surgeons, medical oncologists, and radiation oncologists at Shanghai’s top hospitals
• MDT coordination: Facilitating access to multidisciplinary tumor board review
• Molecular testing coordination: Ensuring comprehensive NGS profiling is performed to identify all actionable targets
• Appointment booking: Priority scheduling across multiple specialties
• Medical interpretation: Professional interpreters for all consultations, biopsy procedures, and treatment discussions
• Second opinion coordination: Arranging second opinions from leading specialists, including remote consultations with international centers
• Insurance coordination: Liaising with your international health insurer for treatment approvals and claims, including for targeted therapies and immunotherapy
• Survivorship support: Coordinating ongoing surveillance, side effect management, and psychological support

📩 Contact CMCS today for a free initial consultation.

Frequently Asked Questions

I don’t smoke. Can I still get lung cancer?
Yes. Approximately 15–20% of lung cancers globally — and a higher proportion in China — occur in never-smokers. Air pollution, cooking fume exposure, radon, family history, and genetic factors all contribute. Non-smoker lung cancer is more likely to harbor actionable mutations (EGFR, ALK) and responds well to targeted therapy.

What is an EGFR mutation and why does it matter?
EGFR (epidermal growth factor receptor) mutations are present in approximately 50% of Chinese lung adenocarcinoma patients. They make the cancer highly sensitive to EGFR tyrosine kinase inhibitors (TKIs) such as osimertinib, which can control the disease for years. Molecular testing to identify EGFR mutations is essential before starting treatment for metastatic NSCLC.

Should I have a lung cancer screening CT scan?
If you are aged 50–80 with a significant smoking history (≥20 pack-years), annual low-dose CT screening is recommended and can reduce lung cancer mortality by over 20%. Non-smokers with other risk factors (air pollution exposure, family history, prior lung disease) should discuss screening with their doctor. CMCS can coordinate LDCT screening as part of a comprehensive health check-up.

Is targeted therapy available in China?
Yes. Osimertinib, alectinib, lorlatinib, and most other targeted agents are approved and available in China. Chinese domestic EGFR TKIs (gefitinib, icotinib) are also widely used. CMCS can assist with accessing the most appropriate targeted therapy and navigating insurance coverage.

How is lung cancer treated if I have no actionable mutation?
For patients without actionable mutations, immunotherapy (PD-1/PD-L1 inhibitors such as pembrolizumab) — alone or in combination with chemotherapy — is the standard first-line treatment for metastatic NSCLC. PD-L1 expression testing guides the choice of regimen. Both imported and domestic immunotherapy agents are available in China.

Is lung cancer treatment covered by international health insurance?
Yes. Lung cancer diagnosis and treatment — including surgery, chemotherapy, radiation, targeted therapy, and immunotherapy — are covered by most international health insurance plans. Coverage for specific newer agents may require pre-authorization. CMCS can verify your coverage and manage the authorization process.